Last update Oct. 23, 2024

Eflornithine Hydrochloride (topical use)

Compatible

Safe product and/or breastfeeding is the best option.

In addition to its uses as an antiparasitic and antineoplastic, eflornithine hydrochloride is also used topically in the form of a twice-daily cream to reduce unwanted facial hair in women. 

Due to its low dermal absorption (> 1%) plasma levels and excretion in breast milk are considered negligible.

In addition, breastfed infants of 30 mothers treated for 7 days with intravenous nifurtimox and eflornithine did not present any problems. (Kuemmerle 2021 & 2020, Schmid 2012)


See below the information of this related product:

Alternatives

We do not have alternatives for Eflornithine Hydrochloride (topical use) since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Eflornithine Hydrochloride (topical use) in other languages or writings:

Groups

Eflornithine Hydrochloride (topical use) belongs to these groups or families:

Tradenames

Main tradenames from several countries containing Eflornithine Hydrochloride (topical use) in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. dermatologist: < 1 %
Molecular weight 237 daltons
T½ 3 hours

References

  1. Schmid C, Kuemmerle A, Blum J, Ghabri S, Kande V, Mutombo W, Ilunga M, Lumpungu I, Mutanda S, Nganzobo P, Tete D, Mubwa N, Kisala M, Blesson S, Mordt OV. In-hospital safety in field conditions of nifurtimox eflornithine combination therapy (NECT) for T. b. gambiense sleeping sickness. PLoS Negl Trop Dis. 2012 Abstract Full text (link to original source)
  2. Pérez JL, Carranza C, Mateos F. Antiparasitarios. Revisión de los fármacos útiles en el tratamiento de parasitosis clásicas y emergentes. \ [Antiparasitic drugs. Review of the useful drugs in the treatment of classic and emergent parasitic diseases]. Rev Esp Quimioter. 2009 Jun;22(2):93-105. Review. Spanish. Abstract Full text (link to original source) Full text (in our servers)
  3. WHO / UNICEF. BREASTFEEDING AND MATERNAL MEDICATION Recommendations for Drugs in the Eleventh WHO Model List of Essential Drugs. Department of Child and Adolescent Health and Development (WHO/UNICEF) 2002 Abstract Full text (link to original source) Full text (in our servers)

Total visits

5,669

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2006 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM